**Abstract**

***Objective:*** The objective was to determine the efficacy and safety of aripiprazole in the maintenance treatment of methamphetamine dependence following methamphetamine psychosis in Thai patients.

***Methods:*** This was a retrospective chart review study in patients aged between 18--65 years with metamphetamine dependence who had been received aripiprazole (dose 2.5--15 mg/day) for at least 2 weeks after resolved from psychosis. Primary outcome was abstinence rate at 12 weeks which was assessed by urine toxicology. Adverse events were reported as secondary outcome.

***Results:*** Forty-three patients were enrolled in this study. Most of them (58.1%) received aripiprazole 10--15 mg/day. The abstinence rate at week 2, 4, 6, 8, 10 and 12 were 90.70%, 88.10%, 78.13%, 76.47%, 91.67% and 75%, respectively. Parkinsonism was the most commonly found adverse events (11.63%), following by insomnia (6.98%), sedation (6.98%) and akathisia (4.65%).

***Conclusions:*** Aripiprazole demonstrated its efficacy in maintaining abstinence from metamphetamine use in Thai patients with metamphetamine dependence following metamphetamine psychosis. It was found to be safe and well tolerated.
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